Shen Cao, Yuhan Wang, Yi Tai, Jing Han, Yanjin Zheng, Can Wang, Hong Xiang Zuo, Ming Yue Li, Yue Xing, Xuejun Jin, Juan Ma
{"title":"Cucurbitacin B alleviates DSS-induced experimental colitis by targeting ZNF70 to suppress the NLRP3/STAT3 signaling axis.","authors":"Shen Cao, Yuhan Wang, Yi Tai, Jing Han, Yanjin Zheng, Can Wang, Hong Xiang Zuo, Ming Yue Li, Yue Xing, Xuejun Jin, Juan Ma","doi":"10.1007/s10787-025-01898-5","DOIUrl":null,"url":null,"abstract":"<p><p>Ulcerative colitis (UC) is an inflammatory disease characterized by lifelong involvement and a complex pathogenesis. Due to the limitations of current treatment modalities, there remains a pressing need to discover new medications for the management of UC. Cucurbitacin B (CuB) is a tetracyclic triterpenoid derived from Lagenaria siceraria (Molina) Standl., exhibiting pharmacological activities including hepatoprotective, anti-inflammatory, and anti-tumor properties. In this study, we conducted a comprehensive evaluation of the anti-inflammatory activity of CuB in both DSS-induced experimental colitis in vivo and macrophage models in vitro. Our results indicate that CuB exerts an anti-inflammatory effect by regulating the assembly of the NLRP3 inflammasome and the activation of p-STAT3 via ZNF70, thereby reducing the release of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α. Such results indicate that CuB can effectively prevent the development of UC and offer new insights for its management.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"5451-5469"},"PeriodicalIF":5.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01898-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Ulcerative colitis (UC) is an inflammatory disease characterized by lifelong involvement and a complex pathogenesis. Due to the limitations of current treatment modalities, there remains a pressing need to discover new medications for the management of UC. Cucurbitacin B (CuB) is a tetracyclic triterpenoid derived from Lagenaria siceraria (Molina) Standl., exhibiting pharmacological activities including hepatoprotective, anti-inflammatory, and anti-tumor properties. In this study, we conducted a comprehensive evaluation of the anti-inflammatory activity of CuB in both DSS-induced experimental colitis in vivo and macrophage models in vitro. Our results indicate that CuB exerts an anti-inflammatory effect by regulating the assembly of the NLRP3 inflammasome and the activation of p-STAT3 via ZNF70, thereby reducing the release of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α. Such results indicate that CuB can effectively prevent the development of UC and offer new insights for its management.
期刊介绍:
Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas:
-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states
-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs
-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents
-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain
-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs
-Muscle-immune interactions during inflammation [...]